We help physicians
Prioritize patients. Deliver the Right Therapy, Faster.
In hospitals today, physicians use isolated, non-specific clinical parameters, such as temperature, heart rate, and blood pressure, but are missing critical biological data that more accurately indicates the patient's health status.
At Prenosis, our decision support tools use artificial intelligence to rapidly synthesize proprietary biological data and historical clinical data to predict future outcomes for existing patients and accelerate optimal therapy.
We provide physicians with real-time information to improve outcomes and reduce hospital costs.
Confidence in Outcomes
Our growing, proprietary ImmunoMap™ enables rapid precision medicine based on evidence from multiple clinical sites1.
70,000+
Biomarker measurements
1,000,000+
Clinical data parameters
2,000+
Comprehensive maps of human immune response
Introducing Immunix™
Physicians make clinical decisions with incomplete information on the patient's full immune profile, which can delay therapy or result in sub-optimal antibiotic selection2.
Our portfolio of decision support tools allows physicians to understand an individual patient's risk profile and prescribe the optimal therapy faster than ever before.
How It Works
Collect
Medical history and bloodwork are collected and tested for patients suspected of having an abnormal immune response.
Analyze
Patient's full immune profile is compared to the Prenosis historical dataset using advanced machine learning algorithms in the cloud to rapidly identify the patients at risk of severe outcomes.
Inform
Immunix™ uses that information to inform the physician's selected treatment pathway and accelerate optimal therapy.
Potential Benefits for U.S. Hospitals
Based on a 1,600 patient, multi-site study3
Reduce mortality
83k
lives per year
Decrease hospital costs
$6.4B
per year
Reduce Hospital
Length of Stay
>2.4M
hospital days per year
Peer Reviewed Articles
07 September 2017
Scientific Reports
Combining Biomarkers with EMR Data to Identify Patients in Different Phases of Sepsis
03 July 2017
Nature Communications
A point-of-care microfluidic biochip for quantification of CD64 expression from whole blood for sepsis stratification
Passionate. Experienced. Practical.
At Prenosis, we are driven to decode the atypical human immune response with simple, easy-to-use tools that help physicians improve patient care and outcomes. Our team has both the expertise and experience to deliver on that promise.
Management Team
Bobby Reddy, Jr., Ph.D.
CEO & CO-FOUNDER
Bobby has led the company from inception, driving company vision, building the team, securing clinical and strategic partnerships, and raising funds...
Read More 
Bobby Reddy, Jr., Ph.D.
CEO & CO-FOUNDER
Bobby has led the company from inception, driving company vision, building the team, securing clinical and strategic partnerships, and raising funds. He has over 12 years of experience in the research and development of early screening technologies for debilitating diseases with a deep understanding of clinical issues. For several years, Bobby has worked intimately with a wide variety of clinical and administrative hospital personnel to comprehensively understand how technology can address the most critical issues they face. He received a Ph.D. in electrical engineering from the University of Illinois at Urbana-Champaign, an M.S. in electrical engineering from the University of California, Irvine, and B.S. degrees in computer engineering and electrical engineering from the University of California, Irvine.
Angela McFarland, CPA, MBA
Chief Financial Officer
Angela is a seasoned CFO with over 15 years experience leading organizations in the biotechnology industry and start-up environment. Previously, she held...
Read More
Angela McFarland, CPA, MBA
Chief Financial Officer
Angela is a seasoned CFO with over 15 years experience leading organizations in the biotechnology industry and start-up environment. Previously, she held the position of CFO for Sony Biotechnology after negotiating the acquisition of the start-up company by Sony Corporation on 2009. Angela began her career in public accounting with PwC. She is a C.P.A. with a bachelor's degree in Public Accounting from Illinois Wesleyan University and an M.B.A. from Warrington College of Business at the University of Florida.
Carlos Lopez-Espina, MS
Director of Analytics
Carlos is an innovator and multidisciplinary problem solver focused on biotechnology, clinical research and product development. Over the last 15 years...
Read More
Carlos Lopez-Espina, MS
Director of Analytics
Carlos is an innovator and multidisciplinary problem solver focused on biotechnology, clinical research and product development. Over the last 15 years he has worked in medical devices and diagnostics in a wide range of disciplines aimed at converting ideas into solutions. In his previous position, Carlos was central in the creation, development, 510k submission/approval, and commercialization of a microfluidics-based Point-of-Care device for global hemostasis management which is currently generating tens of millions of dollars in annual sales. After graduating with an aeronautical engineering degree at the Polytechnic University of Madrid, Carlos moved on to the University of Illinois at Chicago where he earned his M.S. in Mechanical Engineering. Throughout his education and work experience, Carlos has been immersed in all aspects of engineering required to bring a diagnostic device to market.
David Sihai Zhao, Ph.D.
Head of Algorithm Development
Dave has specialized in statistical techniques for analyzing large-scale data from high-throughput biological datasets for over 11 years, and has...
Read More
David Sihai Zhao, Ph.D.
Head of Algorithm Development
Dave has specialized in statistical techniques for analyzing large-scale data from high-throughput biological datasets for over 11 years, and has developed accurate inference and prediction models using multiple omics datasets across varied subjects, phenotypes, modalities, and species. Dave's broad collaborative research experience includes GWAS of pediatric autoimmune disease, eQTL studies of human heart failure, integrative genomics studies of long noncoding RNAs in cancer, and cross-species studies of the molecular roots of social behavior. He is currently an Assistant Professor of Statistics at the University of Illinois at Urbana-Champaign. Dave received a Ph.D. in Biostatistics, and A.M. and A.B. degrees in Statistics and Chemistry/Physics, respectively, all from Harvard University.
Rashid Bashir, Ph.D.
Board Member and Co-Founder
Rashid is an innovation leader in the development of new technologies in the biotechnology field. He has a proven track record of successfully transitioning...
Read More
Rashid Bashir, Ph.D.
Board Member and Co-Founder
Rashid is an innovation leader in the development of new technologies in the biotechnology field. He has a proven track record of successfully transitioning early stage technology to commercial products at both Daktari and BioVitesse. His research interests include BioMEMS, lab on a chip, interfacing of biology and engineering from the molecular to tissue scale, and applications of semiconductor fabrication to biomedical engineering. He is currently the Dean of The Grainger College of Engineering and was previously Executive Associate Dean of the Carle-Illinois College of Medicine and Head of the Department of Bioengineering at the University of Illinois. He has authored or co-authored over 220 journal papers, over 200 conference papers, and has been granted 50 patents.
Advisors
Sean Murphy
Sean is the Executive Vice President of Malin Life Sciences Holding, a publicly traded investment company. Sean was a co-founder of Malin, which has invested approximately $500 Million dollars of...
Read More
Sean Murphy
Sean is the Executive Vice President of Malin Life Sciences Holding, a publicly traded investment company. Sean was a co-founder of Malin, which has invested approximately $500 Million dollars of capital across 18 companies that include pharmaceuticals, medical devices, and healthcare services. He was previously a Senior Advisor at Evercore Partners, a leading investment-banking advisory firm. Prior to his most recent endeavors, Sean was the Head of Corporate M&A and Business Development at Abbott Laboratories. He played a leading role in a number of strategic investments, totaling an excess of $35 Billion, along with running a number of its businesses, during his 30-year career at Abbott.
Mark Wagner
Mark has more than 30 years of global experience in the medical device industry. He most recently served as the President and CEO of Celleration until its acquisition by Alliqua ...
Read More
Mark Wagner
Mark has more than 30 years of global experience in the medical device industry. He most recently served as the President and CEO of Celleration until its acquisition by Alliqua in May 2015. Prior to this, he served as the CEO for Reshape Medical, ProVation Medical, and Survivalink, all of which resulted in successful exits. He currently sits on the Board of Directors of Minnetronix, Zipnosis, Alliqua, and Miromatrix. Mark began his career at GE Healthcare, where he worked in various roles in marketing, business development, and finance. He holds a degree in Business from the University of Southern California.
Edward Ogunro, Ph.D.
Ed served as the Chief Scientific Officer and Senior VP of Research & Development and Regulatory Affairs at Hospira for 4 years. Prior to that, he was the Corporate VP of Hospital Products Research...
Read More
Edward Ogunro, Ph.D.
Ed served as the Chief Scientific Officer and Senior VP of Research & Development and Regulatory Affairs at Hospira for 4 years. Prior to that, he was the Corporate VP of Hospital Products Research & Development at Abbott Laboratories, and served in a number of leadership positions over 20 years with Abbott, primarily in Abbott's Diagnostics Division. He currently serves as an Independent Director on the board of Luminex Corporation.
John Landgraf
John most recently served as the Executive VP of Nutritional Products, one of Abbott's largest businesses. Prior to this, he held roles as the Senior VP of Global Pharmaceutical Manufacturing and Supply...
Read More
John Landgraf
John most recently served as the Executive VP of Nutritional Products, one of Abbott's largest businesses. Prior to this, he held roles as the Senior VP of Global Pharmaceutical Manufacturing and Supply, the VP of Quality Assurance and Compliance for Abbott's Medical Products Group, and various other high-level management positions throughout the course of a 35+ year career with Abbott.
Edwin Moore
Ed is a currently a visiting scientist at the Beckman Institute and an EIR mentor at EnterpriseWorks at UIUC, in addition to serving as the president and co-founder of BioPhia...
Read More
Edwin Moore
Ed is a currently a visiting scientist at the Beckman Institute and an EIR mentor at EnterpriseWorks at UIUC, in addition to serving as the president and co-founder of BioPhia Consulting, a technical consulting firm focused on pharmaceuticals and diagnostics. He has over 30 years of experience in biopharmaceuticals, pharmaceuticals, and clinical diagnostics. He has held positions from bench scientist, R&D Product Development, to Senior Director of Global Analytical Method Development and Validation in both pharmaceuticals and clinical diagnostics at Baxter Healthcare Corp and Abbott Laboratories.
Get in touch.
Chicago Office
3440 S Dearborn Street, Suite 222S
Chicago, IL 60616
P 312-235-3580
